IP Library Granted Patent US 7,108,858
Granted Patent B2
US 7,108,858 · App. 09/897,042 · Granted Sep 19, 2006

Non-anaphylactic forms of allergens and their use

Assignee: Pharmacia Diagnostics AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,108,858
App. No.
09/897,042
Granted
Sep 19, 2006
Kind
B2
Abstract

The present invention is drawn to an immunogen derived from a protein allergen, which is a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen which contains an IgG epitope partly but not wholly overlapping an IgE epitope of the protein allergen; b) a polymeric form of the fragment, in which the fragment constitutes the monomeric units; or c) a non-anaphylactic recombinant polymeric form of the protein allergen having 2–10 monomeric units, in which the protein allergen constitutes the monomeric units. The present invention is further drawn to the use of the immunogen for in vitro diagnoses of type I allergy and hyposensitization.

Claims (13)

1. An immunogen derived from Bet v 1 protein allergen, comprising

a) a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping;

b) a polymeric form of said fragment, in which form the fragment constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker; or

c) a non-anaphylactic recombinant polymeric form of said protein allergen consisting of 2 to 10 monomeric units in which the protein allergen constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker.

2. The immunogen of claim 1 , wherein said immunogen is according to (b) or (c) and said oligopeptide linker comprises 1–30 amino acid residues.

3. The immunogen of claim 2 , wherein said amino acid residues are hydrophilic.

4. An immunogen derived from Bet v 1 protein allergen, comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, wherein the fragment comprises SEQ ID NO: 19.

5. An immunogen derived from Bet v 1 protein allergen, comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, wherein the fragment comprises SEQ ID NO:20.

6. An immunogen derived from Bet v 1 protein allergen, comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, wherein the fragment comprises SEQ ID NO:21.

7. The immunogen of claim 1 , comprising a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping.

8. An immunogen derived from Bet v 1 protein allergen, comprising

a polymeric form of a non-anaphylactic immunogenic recombinant fragment of the protein allergen, said fragment comprising an IgG epitope and an IgE epitope of the protein allergen partly but not completely overlapping, in which form the fragment constitutes the monomeric units, wherein said monomeric units are separated from each other by an oligopeptide linker and

wherein the polymeric form of said fragment is recombinantly produced.

Assignments (2)
CHANGE OF NAME Recorded May 22, 2006
From: PHARMACIA DIAGNOSTICS AB
To: PHADIA AB
Reel/Frame 017670/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 5, 2004
From: PHARMACIA & UPJOHN DIAGNOSTICS AB
To: PHARMACIA DIAGNOSTICS AB
Reel/Frame 015043/0694 →
Priority Claims (1)
SE 9703531 · Sep 30, 1997 · national
Continuity (2)
Continuation 0899854900 · Dec 24, 1997
Related Publication 20020018779A1 · Feb 14, 2002